Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Atilotrelvir in Subjects with Impaired and Normal Liver Function
NCT06106113Phase 1Completed
- Sponsor
- Fujian Akeylink Biotechnology Co., Ltd.
- Start
- Dec 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of atilotrelvir in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Fujian Akeylink Biotechnology Co., Ltd. Primary endpoint: Maximum observed plasma concentration. Started Dec 2022; status: completed.
02
Drugs
atilotrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06106113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06106113.